SCHEMBL3540764

SCHEMBL3540764

O=C(Cc1cccs1)Nc1cccc(-c2nn3ccccc3c2-c2ccnc(Nc3ccc4c(c3)CNCC4)n2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.72
KDR P35968 4/20 0.72
AURKB Q96GD4 4/20 0.72
CDK19 Q9BWU1 2/20 0.72
EGFR P00533 9/20 0.59
IGF1R P08069 9/20 0.59
ERBB2 P04626 8/20 0.59
SLC2A1 P11166 4/20 0.49
MAPK8 P45983 5/20 0.47
MAPK9 P45984 5/20 0.47
MAPK10 P53779 1/20 0.45
ACVR1 Q04771 2/20 0.43
PRKD3 O94806 3/20 0.43
MAP4K4 O95819 3/20 0.43
INSR P06213 3/20 0.43
LCK P06239 3/20 0.43
FYN P06241 3/20 0.43
LYN P07948 3/20 0.43
RET P07949 3/20 0.43
FGFR1 P11362 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13118784 0.92 KDR (0.60) AURKAKDRAURKBCDK19EGFR
SCHEMBL3538140 0.89 EGFR (0.60) AURKAKDRAURKBCDK19EGFR
SCHEMBL3542151 0.88 AURKA (0.55) AURKAKDRAURKBCDK19EGFR
SCHEMBL3545797 0.87 SLC2A1 (0.58) AURKAKDRAURKBCDK19EGFR
SCHEMBL3546062 0.87 KDR (0.55) AURKAKDRAURKBCDK19EGFR
SCHEMBL3543519 0.86 AURKA (0.56) AURKAKDRAURKBCDK19EGFR
SCHEMBL13140688 0.86 AURKA (0.55) AURKAKDRAURKBCDK19EGFR
SCHEMBL3541687 0.86 KDR (0.53) AURKAKDRAURKBCDK19EGFR
SCHEMBL3441882 0.86 AURKA (0.84) AURKAKDRAURKBCDK19EGFR
SCHEMBL13118787 0.86 AURKA (0.55) AURKAKDRAURKBCDK19EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971606-B1 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-04-24 EP disclosed
US-7807673-B2 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-10-05 US disclosed
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors GLAXOSMITHKLINE LLC 2009-06-11 US disclosed
EP-1971606-A2 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS SmithKline Beecham Corporation (US) 2008-09-24 EP disclosed
WO-2007067506-A2 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors ERBB2, ERBB3, ERBB4 AURKA 168/4885KDR 11/4885AURKB 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.